US Stock Market Move | Latigo Biotherapeutics (LTGO.US) debuts on the U.S. stock market, with its stock price rising over 14% after opening.
As of the time of this report, the stock has risen over 14%, trading at $20.53.
On Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) debuted on the US stock market. As of this writing, the stock is up over 14%, trading at $20.53. Latigo is committed to developing non-opioid analgesics targeting the Nav1.8 sodium ion channel. Its core candidate, LTG-001, is an oral Nav1.8 inhibitor primarily used for treating moderate to severe acute pain, including postoperative pain. This drug aims to provide analgesic effects comparable to those of opioids while avoiding the risk of addiction. Nav1.8 is primarily expressed in peripheral pain-sensing neurons, and its inhibitors do not act on the central nervous system, thus lacking addictive properties.
Related Articles
US Stock Market Move | Ticketplus Ltd (TP.US) debuted on the U.S. stock market, dropping over 15% after opening.
In July, the U.S. non-farm payroll unexpectedly turned negative, dealing a heavy blow to the dollar. The market has lowered its expectations for a rate hike in September, and the Federal Reserve may continue to hold its position.
US Stock Market Move | BlossomHill Therapeutics (BLSM.US) debuts on the US stock market, with the stock price slightly declining after opening.
US Stock Market Move | Ticketplus Ltd (TP.US) debuted on the U.S. stock market, dropping over 15% after opening.
In July, the U.S. non-farm payroll unexpectedly turned negative, dealing a heavy blow to the dollar. The market has lowered its expectations for a rate hike in September, and the Federal Reserve may continue to hold its position.
US Stock Market Move | BlossomHill Therapeutics (BLSM.US) debuts on the US stock market, with the stock price slightly declining after opening.
RECOMMEND
